Foster & Motley Inc. Decreases Stake in Danaher Co. (NYSE:DHR)

Foster & Motley Inc. cut its holdings in Danaher Co. (NYSE:DHR) by 23.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 950 shares of the conglomerate’s stock after selling 287 shares during the quarter. Foster & Motley Inc.’s holdings in Danaher were worth $264,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. nVerses Capital LLC purchased a new stake in shares of Danaher in the second quarter valued at approximately $25,000. CarsonAllaria Wealth Management Ltd. purchased a new stake in Danaher during the second quarter worth $25,000. MFA Wealth Advisors LLC purchased a new stake in Danaher during the second quarter worth $51,000. Financial Connections Group Inc. purchased a new stake in Danaher during the second quarter worth $51,000. Finally, Western Pacific Wealth Management LP purchased a new stake in Danaher during the first quarter worth $55,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.90% of the stock is owned by company insiders.

Danaher Price Performance

DHR stock opened at $246.10 on Friday. The stock has a 50-day moving average price of $265.79 and a two-hundred day moving average price of $260.75. Danaher Co. has a 12-month low of $192.35 and a 12-month high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The company has a market cap of $177.75 billion, a PE ratio of 46.97, a price-to-earnings-growth ratio of 4.54 and a beta of 0.85.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the previous year, the business earned $2.02 earnings per share. The firm’s quarterly revenue was up 3.1% compared to the same quarter last year. As a group, research analysts predict that Danaher Co. will post 7.51 EPS for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on DHR shares. Stifel Nicolaus boosted their target price on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Evercore ISI boosted their target price on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. KeyCorp boosted their price target on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. StockNews.com raised Danaher from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, TD Cowen boosted their price target on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.